US 12,440,444 B2
Matrix bound vesicles (MBVS) containing IL-33 and their use
Stephen Francis Badylak, West Lafayette, IN (US); George S. Hussey, Cranberry Township, PA (US); Heth Turnquist, Pittsburgh, PA (US); Jenna Lynn Dziki, Pittsburgh, PA (US); Quan Liu, Shenzhen (CN); and Zhongqiang Zhang, Changsha (CN)
Assigned to University of Pittsburgh—Of the Commonwealth System of Higher Education, Pittsburgh, PA (US)
Appl. No. 17/052,034
Filed by University of Pittsburgh—Of the Commonwealth System of Higher Education, Pittsburgh, PA (US)
PCT Filed May 3, 2019, PCT No. PCT/US2019/030547
§ 371(c)(1), (2) Date Oct. 30, 2020,
PCT Pub. No. WO2019/213482, PCT Pub. Date Nov. 7, 2019.
Claims priority of provisional application 62/666,624, filed on May 3, 2018.
Prior Publication US 2021/0106526 A1, Apr. 15, 2021
Int. Cl. A61P 9/10 (2006.01); A61K 9/127 (2006.01); A61K 31/7105 (2006.01); A61K 38/20 (2006.01); A61K 38/44 (2006.01); A61K 45/06 (2006.01); A61L 27/36 (2006.01)
CPC A61K 9/127 (2013.01) [A61K 31/7105 (2013.01); A61K 38/20 (2013.01); A61K 38/44 (2013.01); A61K 45/06 (2013.01); A61L 27/3633 (2013.01); A61P 9/10 (2018.01); C12Y 104/03013 (2013.01)] 15 Claims
OG exemplary drawing
 
1. A method for treating or inhibiting heart transplant rejection in a subject who has received a hear transplant comprising:
administering to the subject who has received a heart transplant a therapeutically effective amount of isolated nanovesicles derived from an extracellular matrix, wherein the nanovesicles comprise interleukin (IL)-33 and lysyl oxidase, and wherein the nanovesicles a) do not express CD63 or CD81, or b) are CD63loCD81lo,
thereby treating or inhibiting heart transplant rejection in the subject.